AR056194A1 - Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular - Google Patents

Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular

Info

Publication number
AR056194A1
AR056194A1 ARP060103941A ARP060103941A AR056194A1 AR 056194 A1 AR056194 A1 AR 056194A1 AR P060103941 A ARP060103941 A AR P060103941A AR P060103941 A ARP060103941 A AR P060103941A AR 056194 A1 AR056194 A1 AR 056194A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
alkylene
alkyl
independently selected
Prior art date
Application number
ARP060103941A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0518671A external-priority patent/GB0518671D0/en
Priority claimed from GB0518672A external-priority patent/GB0518672D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR056194A1 publication Critical patent/AR056194A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composicion que comprende un inhibidor del receptor del factor de crecimiento endotelial vascular y un potenciador de la penetracion, y usos de la misma. Reivindicacion 2: Una composicion de la reivindicacion 1, en donde el inhibidor del receptor del factor de crecimiento endotelial vascular es un compuesto de formula(1), en donde R1 es H; halogeno; -(C0-7)-R3; -(C0-7)-NR4R5; o -C(=O)-R6; R2 cicloalquilo C3-8 substituido; arilo substituido; o heterociclilo substituido; R3 es H o alquilo C1-4 insubstituido o substituido; R4 y R5 se seleccionan independientemente a partir del grupo que consiste en H; alquilo C1-4 insubstituido o substituido; alquil C1-4-carbonilo, en donde la fraccion de alquilo C1-4 está opcionalmente substituida; y alcoxi C1-4-carbonilo, en donde la fraccion de alquilo C1-4 está opcionalmente substituida; R6 es H; alquilo C1-4 insubstituido o substituido; aIcoxilo C1-4, en donde la fraccion de alquilo C1-4 está opcionalmente substituida; o amino insubstituido, mono- o di-substituido; A, B y X se seleccionan independientemente a partir de =C(R7)- o N; E, G y T se seleccionan independientemente a partir de =C(R8)- o N; R7 y R8 se seleccionan independientemente a partir del grupo que consiste en H, halogeno y alquilo C1-4 insubstituido o substituido; Y es -O-, -S-, -S(O)-, -S(O)2-, -CH2- o -CH2-CH2-; Z es CH o N y Q es alquileno C1-4 o alquenileno C2-4 en donde alquileno C1-4 o alquenileno C2-4 pueden estar opcionalmente substituidos y en donde uno o más de los átomos de carbono de esta cadena de alquileno C1-4 o alquenileno C2-4 pueden ser opcionalmente reemplazados por un heteroátomo independientemente seleccionado a partir de nitrogeno, oxígeno y azufre; y el enlace entre Q y Z caracterizado por una línea punteada es un enlace individual; con la condicion de que si Z es N, Q no es alquileno insubstituido no ramificado; o Z es C y Q es como se define anteriormente, en donde el enlace entre Q y Z caracterizado por una línea punteada es un doble enlace; y W no está presente o es alquileno C1-3; o un compuesto de formula (2), en donde R9 y R10 son cada uno independientemente uno del otro, hidrogeno, alquilo C1-7 insubstituido o substituido o cicloalquilo C3-8, un radical heterocíclico enlazado por medio de un átomo de carbono del anillo, o un radical de la formula R12-Y-(C=Z)-, en donde R12 es amino insubstituido, mono-, o di-substituido o un radical heterocíclico, Y no está presente o es alquilo C1-8 y Z es O, S o imino, con la condicion de que R9 y R10 no sean ambos hidrogeno; o R9 y R10 junto con el átomo de nitrogeno con el que están unidos forman un radical heterocíclico; R11 es un radical heterocíclico o un radical aromático insubstituido o substituido; K es alquileno C1-7, -C(=O)-, o alquileno C1-6-C(=O)-, en donde el grupo carbonilo está unido a la fraccion NR9R10; M es -NH- u -O-, con la condicion de que M es -O- si K es -C(=O)- o alquileno C1-6-C(=O)-; y V no está presente o es alquileno C1-7, con la condicion de que un radical heterocíclico R11 está enlazado por medio de un átomo de carbono del anillo si V no está presente, o un tautomero del mismo; o un derivado de 4-piridilmetil-ftalazina; o un tautomero del mismo, o en la forma de una sal, un solvente, o en la forma de una sal y un solvente. Reivindicacion 6: Una composicion de cualquiera de las reivindicaciones 1 a 5, en donde el inhibidor del receptor del factor de crecimiento endotelial vascular es un compuesto de la formula (3) o una sal farmacéuticamente aceptable del mismo.
ARP060103941A 2005-09-13 2006-09-11 Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular AR056194A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0518671A GB0518671D0 (en) 2005-09-13 2005-09-13 Organic compounds
GB0518672A GB0518672D0 (en) 2005-09-13 2005-09-13 Organic compounds

Publications (1)

Publication Number Publication Date
AR056194A1 true AR056194A1 (es) 2007-09-26

Family

ID=37663150

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103941A AR056194A1 (es) 2005-09-13 2006-09-11 Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular

Country Status (23)

Country Link
US (2) US20080306058A1 (es)
EP (1) EP1945217B1 (es)
JP (1) JP2009507871A (es)
KR (1) KR20080058376A (es)
AR (1) AR056194A1 (es)
AT (1) ATE555790T1 (es)
AU (1) AU2006291526B2 (es)
BR (1) BRPI0615881A2 (es)
CA (1) CA2621399A1 (es)
EC (1) ECSP088259A (es)
GT (1) GT200600411A (es)
IL (1) IL189984A0 (es)
MA (1) MA29788B1 (es)
MY (1) MY145751A (es)
NO (1) NO20081807L (es)
NZ (1) NZ566474A (es)
PE (1) PE20070457A1 (es)
RU (1) RU2424804C2 (es)
SA (1) SA06270315B1 (es)
SG (1) SG165371A1 (es)
TN (1) TNSN08112A1 (es)
TW (1) TWI325321B (es)
WO (1) WO2007031265A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0605120D0 (en) * 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
KR20100016584A (ko) * 2007-04-17 2010-02-12 노파르티스 아게 암 치료제로서의 나프탈렌 카르복실산 아미드의 에테르
AU2008288898B2 (en) * 2007-08-22 2014-08-07 Allergan, Inc. Therapeutic quinoline and naphthalene derivatives
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US20110112121A1 (en) 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
WO2012094451A1 (en) * 2011-01-06 2012-07-12 Beta Pharma Canada Inc. Novel ureas for the treatment and prevention of cancer
EP2786752B1 (en) * 2011-12-01 2019-06-12 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
US10149834B2 (en) 2011-12-01 2018-12-11 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
CA2908849C (en) * 2013-04-09 2017-11-07 Guangzhou Hui Bo Rui Biological Pharmaceutical Technology Co., Ltd. Anti-angiogenesis compound, intermediate and use thereof
EP3064489A4 (en) * 2013-11-01 2017-06-21 Ube Industries, Ltd. Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof
CN104860885B (zh) 2014-02-24 2017-11-17 中国科学院上海药物研究所 萘酰胺类化合物、其制备方法和用途
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
CN107098884A (zh) * 2016-02-19 2017-08-29 中国科学院上海药物研究所 一类取代的氨基吡啶类化合物及其制备和用途
JP2023515630A (ja) * 2020-02-28 2023-04-13 上▲海▼▲潤▼石医▲薬▼科技有限公司 Ｃｓｆ－１ｒキナーゼ阻害剤の使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5879690A (en) * 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
US6355657B1 (en) * 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
AU6998000A (en) * 1999-08-27 2001-03-26 Boehringer Ingelheim Pharma Kg Substituted indolinones as tyrosine kinase inhibitors
EP1330452B1 (en) * 2000-09-20 2008-11-26 Ortho-McNeil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
ES2318649T3 (es) * 2000-10-20 2009-05-01 EISAI R&D MANAGEMENT CO., LTD. Procedimiento de preparacion de derivados de 4-fenoxi quinolinas.
EP2324825A1 (en) * 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
US20040043026A1 (en) * 2002-05-13 2004-03-04 Tai-Lan Tuan Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
NZ538617A (en) * 2002-08-30 2005-12-23 Eisai Co Ltd Azaarene derivatives
WO2004103159A2 (en) * 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
EP1660503A1 (en) * 2003-08-29 2006-05-31 Pfizer Inc. Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
WO2005069906A2 (en) * 2004-01-16 2005-08-04 Yale University Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
AU2005206571B8 (en) * 2004-01-23 2010-09-02 Amgen Inc. Compounds and methods of use
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa

Also Published As

Publication number Publication date
RU2008114048A (ru) 2009-10-20
BRPI0615881A2 (pt) 2011-05-31
MA29788B1 (fr) 2008-09-01
TNSN08112A1 (en) 2009-07-14
NO20081807L (no) 2008-05-16
MY145751A (en) 2012-03-30
TW200744600A (en) 2007-12-16
KR20080058376A (ko) 2008-06-25
GT200600411A (es) 2007-05-21
TWI325321B (en) 2010-06-01
EP1945217A2 (en) 2008-07-23
US20080306058A1 (en) 2008-12-11
RU2424804C2 (ru) 2011-07-27
ATE555790T1 (de) 2012-05-15
AU2006291526B2 (en) 2010-07-29
CA2621399A1 (en) 2007-03-22
EP1945217B1 (en) 2012-05-02
SA06270315B1 (ar) 2010-12-21
JP2009507871A (ja) 2009-02-26
WO2007031265A3 (en) 2007-07-12
ECSP088259A (es) 2008-04-28
PE20070457A1 (es) 2007-06-06
US20120172386A1 (en) 2012-07-05
NZ566474A (en) 2011-05-27
WO2007031265A2 (en) 2007-03-22
SG165371A1 (en) 2010-10-28
IL189984A0 (en) 2008-11-03
AU2006291526A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
AR056194A1 (es) Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
AR050932A1 (es) Amidas biciclicas como inhibidores de cinasa
ES2564179T3 (es) Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales
AR118123A2 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos, composición farmacéutica y combinación
AR105640A1 (es) Derivados heterobicíclicos microbicidas
AR055774A1 (es) Fenilacetamidas apropiadas como inhibidores de proteina quinasa
CO6180506A2 (es) Inhibidores de la proteasa ns3 del hcv
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
AR054809A1 (es) Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
AR044874A1 (es) Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica
ES2531023T3 (es) Derivados de isoxazolo-piridina
AR072936A1 (es) Derivados piridazin y pirimidin condensados con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos como agentes anticancer.
AR088449A1 (es) Benzilindazoles sustituidos
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
CO6160266A2 (es) Derivado de oxopirazina y herbicida
CO6300865A2 (es) Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica
PE20130187A1 (es) Bis(difluorometil) pirazoles como fungicidas
AR052343A1 (es) Analogos de tetrahidroquinolina como agonistas muscarinicos
AR093438A2 (es) Compuestos fenolicos policiclicos como estabilizantes
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR082696A1 (es) Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras
PE20081844A1 (es) DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a

Legal Events

Date Code Title Description
FA Abandonment or withdrawal